CURRICULUM VITAE

NAME: George J. Atiee, M.D.

ADDRESS: GSA Research
2108 NW Military Hwy
San Antonio, Texas 78213

Healthcare Discoveries, Inc.
8307 Gault Lane
San Antonio, Texas 78209

BUSINESS PHONE: 210-348-6635
210-798-5115

BUSINESS FAX: 210-342-6815
210-616-0408

		DATE
EDUCATION:	BA, St. Mary's University, San Antonio, TX	1981
	MD, U.T. Health Science Center, San Antonio, TX	1985
	Internship, Baylor College of Medicine, Houston, TX	1985-1986
	Residency, Baylor College of Medicine, Houston, TX Co-chief resident third year of residency	1986-1988
LICENSES:	Medical Doctor License # H0143	1985-present
BOARD CERTIFIED:	Family Practice	1988-present
MILITARY EXP:	Air Force Active Duty	08/1980-08/1991
HIGHEST RANK:	Major	
MILITARY POSITION:	Chief of Primary Care Clinic, Randolph Air Force Base, TX	
MEDICAL SOCIETIES:	Bexar County Medical Society Texas Medical Association Texas Academy of Family Physicians American Academy of Family Physicians	

		DATE
PRACTICE SITUATION:	Private Practice	05/00-present
	WellMed	06/99-04/00
	Cinnamon Creek Medical Group	1993-1999
	Trinity Medical Group	06/91-12/92

CLINICAL INVESTIGATOR:

	Healthcare Discoveries 8109 Fredericksburg Rd. St.300 San Antonio, TX	01/05-present
	GSA Research 2108 NW Military Hwy San Antonio, TX 78213	2003-present
	Sun Research Institute 730 N. Main Ave., Ste. 424 San Antonio, TX 78205	1995-09/03

ACTIVITIES:	Team Physician Antonian High School	1999-present
	Athletic Booster Club President Antonian High School	2001-2002
	St. Paul Catholic Church Chairman of Committee Project 2000	1995-1997

XXXX – 2007 (INVESTIGATOR)

A PHASE I, SINGLE-CENTER, OPEN-LABEL, SAFETY AND ABSORBTION EVALUATION OF X (X) 3% CREAM AND X (X) 0.3% CREAM FOLLOWING TOPICAL EXPOSURE IN HEALTHY JAPANESE SUBJECTS AGED 18 TO 50 YEARS

XXXX – 2007 (INVESTIGATOR)

A MULTIPLE-CENTER, OPEN-LABEL, MULTIPLE-DOSE, THREE PERIOD, SINGLE SEQUENCE CROSSOVER STUDY TO INVESTIGATE THE POTENTIAL PHARMACODYNAMIC AND POTENTIAL PHARMACOKINETIC INTERACTION BETWEEN X AND X IN TYPE II DIABETIC (T2D) PATIENTS NOT ADEQUATELY CONTROLLED WITH X AS A STANDARD PRESCRIBED THERAPY

XXXX – 2007 (INVESTIGATOR)

A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY COMPARING THE ANALGEIC EFFICACY AND SAFETY OF EXTENEDE-RLEASE X TO PLACEBO IN SUBJECTS WITH ACUTE PAIN FOLLOWING BUNIONECTOMY

XXXX – 2007 (INVESTIGATOR)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLED STUDY OF THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF ESCALATING DOSES OF X IN NORMAL HEALTHY SUBJECTS

XXXX – 2007 (INVESTIGATOR)

PHASE I, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, 3-PERIOD CROSSOVER STUDY TO INVESTIGATE THE PHARAMCOKINETICS, PHARMACODYNAMICES, SAFETY AND TOLERABILITY OF X NASAL AEROSOL

XXXX – 2006/2007 (INVESTIGATOR)

A SINGLE-DOSE, TWO-TREATMENT, TWO-PERIOD, RANDOMIZED, OPEN-LABEL, TWO-WAY CROSS OVER STUDY TO CHARACTERIZE THE PHARMACOKINETIC PROFILE OF A SINGLE DOSE OF X VS. X IN FASTED STATE AMONG HEALTHY ADULT VOLUNTEERS

XXXX – 2006/2007 (INVESTIGATOR)

AN OPEN-LABEL, RANDOMIZED, MULTI-SITE STUDY TO ASSESS THE PHARMACOKINETICS OF SINGLE SUBCUTANEOUS INJECTIONS OF 16MG AND 64MG OF X ADMINISTERED AT THREE DIFFERENT INJECTION SITES IN ADULT MALE AND FEMAL SUBJECTS WITH THYPE II DIABETES AND OF SINGLE SUBCUTANEOUS INJECTIONS OF 16MG AND 64MG OF X ADMINISTERED IN ABDOMEN OF HELATHY, NORMAL VOLUNTEERS

XXXX – 2006/2007 (INVESTIGATOR)

A PHASE II, RANDOMZIED, DOUBLE-BLIND, PLACEBOT-CONTROLLED STUDY TO EVALUATE THE EFFECT OF X ON HDL-CHLESTEROL IN AUDLT SUBJECTS WITH DYSLIPIDEMIA AND TYPE II DIABETES MELLITUS

XXXX – 2006/2007 (INVESTIGATOR)

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL-GROUP, ASCENDING SINGLE DOSE STUDY OF THE SAFETY. TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMICS OF X ADMINISTERED SUBCUTANEOUSLY AND INTRAVENOUSLY TO SUBJECTS WITH ASTHMA

XXXX – 2006 (INVESTIGATOR)

AN EXTENSION TO STUDY TS033-US201: PAHSE IIA, SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS EFFECTS OF MULTIPLE ESCALATING DOSES OF X IN SUBJECTS WITH TYPE II DIABETES

XXXX – 2006 (INVESTIGATOR)

A 2-PERIOD, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, RISING, SINGLE, ORAL DOSE TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF X IN HEATLHY ELDERLY SUBJECTS

XXXX – 2006 (INVESTIGATOR)

A MULTIPLE-CENTER, OPEN-LABEL, RANDOMIZED, SIX-SEQUENCES, THREE-WAY CROSSOVER STUDY TO INVESTIGATE THE POTENTIAL PHARMACOKINETIC INTERACTION BETWEEN X AND SIMVASTATIN IN TYPE 2 DIABETIC PATIENTS

XXXX – 2006 (INVESTIGATOR)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLED, SEQUENTIAL, SERIAL-PANEL, RISING-MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERBILITY, AND PHARMACOKINETICS OF X AND THE EFFECT OF MULTIPLE DOSES OF X ON THE PHARMACOKINETICS OF X IN HEALHTY MALE SUBJECTS

XXXX – 2006 (INVESTIGATOR)

AN OPEN-LABLE, 2-PERIOD, CROSSOVER STUDY TO INVESTIGATE THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF THE X PEDIATRIC ETHYLCELLULOSE AND ADULT X TABLET FORMULATIONS IN HEALTHY ADULTS

XXXX – 2006 (INVESTIGATOR)

A 24-MONTH DOUBLE-BLIND, RANDOMIZED, MULTICENTERK, PLACEBO-CONTROLED, PARRALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 0.5MG AND 1.25MG X ADMINISTERED ORALLY ONCE DAILY VERSUS PLACEBO IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

XXXX – 2006 (INVESTIGATOR)

PHASE I, OPEN-LABEL, SINGLE-DOSE, SINGLE-CENTER, TREATMENT SEQUENCE-RANDOMIZED, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS, BIOAVAILABILITY, AND SAFETY OF INTRAMUSCULAR X ADMINISTERED TO HEALTHY SUBJECTS

XXXX – 2006 (INVESTIGATOR)

PHARMACODYNAMIC DOSE-RESPONSE OF X 30MG, 60MG, 90MG AND 120MG IN HEALTHY VOLUNTEERS

XXXX – 2006 (INVESTIGATOR)

A PHASE I DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF INTRAVENOUS X ADMINISTERED ONCE DAILY FOR ONE DAY AND AS REPEAT DOSES FOR TEN DAYS IN HEALTHY SUBJECTS

XXXX – 2006 (INVESTIGATOR)

A PHASE I DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATING SUTDY TO EVLAUATE THE SAFETY AND TOLERABILITY OF INTRAVENOUS X ADMINISTERED TWICE DAILY IN HEALHTY SUBJECTS

XXXX – 2006 (INVESTIGATOR)

A PROTSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY OF A X VACCINE OF NEW 6:2 X VIRUS REASSORTANTS IN HEALTHY ADULTS

XXXX – 2006 (INVESTIGATOR)

A PHASE I, SINGLE-CENTER, RNADOMIZED, OPEN-LABEL, PARALLEL GROUP, MULITPLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF X (30MG, 60MG, AND 90MG) IN SUJBECTS WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD)

XXXX – 2006 (INVESTIGATOR

A RANDOMIZED, MULTIPLE-DOSE, DOSE-ESCALATION, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE I TRIAL INVESTIGATING THE OPTIMAL SAFE DOSE OF ALK RAGWEED TABLET X IN ADULT SUBJECTS WITH SEASONAL RHINOCONJUNCTIVITIS CAUSED BY RAGWEED POLLEN ALLERGY

XXXX – 2006 (INVESTIGATOR)

PHASE I, SINGLE-CENTER, OPEN-LABEL, REPEAT-DOSE TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND DISTRIBUTION, METABOLIXM, AND EXCRETION OF X IN NORMAL VOLUNTEERS

XXXX – 2006 (INVESTIGATOR)
MULITPLE ASCENDING DOSE STUDY OF X IN PATIENTS WITH STABLE RHEUMATOID ARTHRITIS ON A METHOTRESXATE BACKGROUND

XXXX – 2006 (INVESTIGATOR)
A PHASE I, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED MULTI-DAILY INTRAVENOUS ADMINISTRATION STUDY TO EVALUATE THE SAFETY, TOLERABLILITY, AND PHARMACOKINETICS OF X IN HEALTHY ELDERLY SUBJECTS AND DIABETIC PATIENTS (TYPE I AND TYPE 2)

XXXX – 2006 (INVESTIGATOR)
A PHASE IB, SIGNLE-CENTER, BLINDED, PLACEBO-CONTROLLED, DOSE ESCALATION TRIAL TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF X ADMINSTERED AS A CONTINOUS INTRAVENOUS INFUSION IN HEALTHY VOLUNTEERS EMPLOYING THE HUMAN ENDOTOXIN MODEL

XXXX – 2006 (INVESTIGATOR)
AN OPEN-LABEL, RANDOMIZED, 2-PANEL, 2-PERIOD, CORSSOVER STUDY TO INVESTIGATE THE INFLUENCE OF X ON X SIGNLE DOSE PHARMACOKINETICS IN HEALTHY MALE SUBJECTS

XXXX – 2006 (INVESTIGATOR)
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY DESINGED TO ASSESS THE EFFECTS OF 300MG OF X AND X (X) ON THE LIPOPROTEIN PORIFLE OF EACH DRUG (X AND X) DURING A 4 MONTH TREATMENT PERIOD IN SUBJECTS WHO ARE NOT RECEIVING OTHER LIPID REGULATING DRUGS

XXXX – 2006 (INVESTIGATOR)
PHASE IIA, SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIC EFFECTS OF MULTIPLE ESCALATING DOSES OF X IN SUBJECTS WITH TYPE II DIABETES MELLITUS

XXXX – 2006 (INVESTIGATOR)
A MULIT-DOSE SAFETY AND PHAMRACOKINETICS STUDY OF X AT 60MG ECRAPROST DOSE ADMINISTERED BY INTRAVENOUS INJECTION TO HEALTHY VOLUNTEERS 55 YEARS OF AGE OR OLDER

XXXX – 2006 (INVESTIGATOR)
A PHASE I, OPEN LABLE, PARALLEL STUDY TO EVALUATE THE EFECT OF GENDER AND AGE ON THE PHARMACOKINETICS AND SAFETY OF A SIGNLE ORAL DOSE OF X 60MG

XXXX – 2005/2006 (INVESTIGATOR)
A TWO-PART, DOUBLE-BLIND, RANDOMIZED, PLACEB-CONTROLLED, RISING MULITPLE-DOSE STUDY TO INVESTIGATE THE EFFECT OF ONCE OR TWICE DAILY DOSES OF X ON PLASMA Aß PEPTIDE LEVELS, PHARMACOKINETICS PROFILES, SAFETY AND TOLERABILITY IN HEALTHY ELDERLY MALE AND FEMALE VOLUNTEERS

XXXX – 2006 (INVESTIGATOR)
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 3-PERIOD CROSSOVER STUDY TO EXPLORE THE ADDITIVE EFFECT OF X TO X (ER X) ON FLUSHING SYMPTOMS OF HEALTHY SUBJECTS

XXXX – 2005 (INVESTIGATOR)
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, DOUBL-DUMMY, 4-PERIOD, SINGLE-DOSE, CROSSOVER STUDY TO ASSESS THE EFFECTS OF X ON QTC INTERVAL IN HEALTHY VOLUNTEERS

XXXX – 2005 (INVESTIGATOR)
A RANDOMIZAED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS AFTER ADMINISTRATION OF MULITPLE DOSES OF X TO PATIENTS WITH TYPE II DIABETES

XXXX – 2005 (INVESTIGATOR)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE ESCALATION EVALUATION OF THE MAXIMUM TOLERATED DOSE OF X IN HEALTHY MALE SUBJECTS

XXXX – 2005 (INVESTIGATOR)
AN OPEN-LABEL, 2-PERIOD, FIXED0SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF X ON THE PHARMACOKINETICS OF X IN HELATHY ADULT SUBJECTS

XXXX – 2005 (INVESTIGATOR)
AN OPEN-LABEL, RANDOMIZED, FOUR-PERIOD CROSSOVER STUDY IN HEALTHY SUBJECTS TO DEMONSTRATE THE BIOEQUIVALENCE OF A FIXED DOSE COMBINATION TABLET FROMULATION OF X (8MG/80MG) TO CONCOMITANT DOSING OF X 8MG AND X 80MG COMMERCIAL TABLETS AND TO ASSESS THE PHARMACOKINETICS OF THE CONCOMITANT DOSING OF X 8MG AND X 80MG COMMERCIAL TABLETS RELATIVE TO COMMERCIAL X 8MG ALONGE, AND COMMERCIAL X 80MG ALONE, IN HEALTHY SUBJECTS

XXXX – 2005 (INVESTIGATOR)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF X IN HEALTHY ELDERLY MALE, ELDERLY FEMAKL AND YOUNG FEMALE VOLUNTEERS

XXXX – 2005 (INVESTIGATOR)
A PHASE I, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, SINGLE ASCENDING INTRAVENOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF X IN HEALTHY ADULT SUBJECTS

XXXX – 2005 (INVESTIGATOR)
A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY OF BIVALENT VACCINE OF NEW 6:2 X VIRUS REASSORTANTS IN HEALTHY ADULTS

XXXX – 2005 (INVESTIGATOR)
A OPEN-LABEL, SINGLE DOSE, 2-PERIOD REPLICATE DESIGN PILOT BIOEQUIVALENCY STUDY OF X 100MG TABLETS UNDER FASTED CONDITIONS

XXXX – 2005 (INVESTIGATOR)
A PHASE I, DOUBLE-BLIND, PLACEBO-CONTROLLED, ASCENDING DOSE MULTIPLE INTRAVENOUS DOSE, SAFETY AND PHARMACOKINETIC STUDY OF X IN HEALTHY ADULT MALE AND FEMALE SUBJECTS

XXXX – 2005 (INVESTIGATOR)
AN OPEN-LABEL, RANOMIZED, SINGLE DOSE 6-WAY CROSSOVER STUDY TO INVESTIGATE THE PHARMACOKINETICSM, SAFETY AND TOLERABILITY OF X FORMULATIONS IN HELATHY MALE VOLUNTEERS

XXXX-2005 (INVESTIGATOR)
AN OPEN-LABEL, SINGLE-DOSE, RANDOMIZED, CROSS-OVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF X 300MG FORMULATED AS AN IMMEDIATE RELEASE TABLET MADE BY DIRECT COMPRESSION, AN IMMEDIATE RELEASE TABLET MADE BY WET GRANULATION AND AN ENTERIC COATED IMMEDIATE RELEASE TABLET MADE BY WET GRANULATION

XXXX-2005 (INVESTIGATOR)
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY DESIGNED TO ASSES THE EFFECTS OF 300MG OF X ON THE LIPOPROTEIN PROFILE (INCLUDING HDL-C AND LDL-C) DURING A 3 MONTH TREATMENT PERIOD IN SUBJECTS WHO ARE NOT RECEIVING OTHER LIPIF-REGULATING DRUGS

XXXX-2005 (INVESTIGATOR)
AN OPEN-LABEL, MULTIPLE DOSE CLINICAL TRIAL TO ASSESS THE EFFECT OF ORALLY ADMINISTERED X AT 1,200 MG PER DAY ON QTc INTERVAL, OVERALL SAFETY, AND DOSAGE TOLERABILITY IN HEALTHY SUBJECTS

XXXX-2005 (INVESTIGATOR)
INVESTIAGATION OF POTENTIAL ADDITIVE INHIBITORY EFFECTS ON HPA-AXIS OF X NASAL SPRAY WHEN ADMINISTERED CONCOMITANTLY WITH ORALLY INHALED X IN PATIENTS (18-60 YEARS) WITH PERENNIAL ALLERGIC RHINITIS

XXXX – 2005 (INVESTIGATOR)
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE 6-WAY CROSSOVER STUDY TO INVESTIGATE THE PHAMACOKINETICS, SAFETY AND TOLERABLILITY OF X FORMULATIONS IN HEALTHY MALE VOLUNTEERS

A RANDOMIZED, DOUBLE BLIND, ACTIVE COMPARATOR CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY OF XX IN PATIENTS WITH OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS

STUDY OF XX IN WOMAN OF DIFFERENT DEMOGRAPHIC CHARACTERISTICS AND CO-MORBIDITIES WITH XX EVALUATION OF EFFICACY AND SAFETY

XXX EXPERIENCE DOCUMENTED IN A CONSUMER TRIAL (XXX) XXX:
A MULTICENTER, RANDOMIZED PARALLEL, OPEN-LABEL, ACTUAL USE STUDY WITH XX (XX) TO ASSESS CONSUMER BEHAVIOR, COMPLIANCE, AND SAFETY IN A SIMULATED OTC-LIKE AND RX-LIKE POPULATION

(XX) XXX PROTOCOL XX
A CONTROLLED SURVEILLANCE STUDY OF ASTHMA EVENT OUTCOMES IN SUBJECTS RECEIVING EITHER USUAL PHARMACOTHERAPY OF ASTHMA OR USUAL PHARMACOTHERAPY PLUS XX 42MCG (2PUFFS) TWICE DAILY

PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING XX 300MG PO BID FOR 10 DAYS WITH XX 200MG PO BID FOR 14 DAYS IN THE TREATMENT OF PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA

A PHASE 2, RANDOMIZED, TRIPLE BLIND, PLACEBO-CONTROLLED, MULTICENTER, FORCED DOSE-ESCALATION STUDY TO EXAMINE DOSE TOLERABILITY IN SUBJECTS WITH TYPE 2 DM GIVEN XXX SUBCUTANEOUSLY

A PHASE 2, RANDOMIZED, TRIPLE BLIND, PLACEBOT-CONTROLLED, MULTICENTER, FORCED DOSE-ESCALATION STUDY TO EXAMINE DOSE TOLERABILITY IN SUBJECTS WITH TYPE 2 DM GIVEN XX SUBCTANEOUSLY

THE EVALUATION OF XX ADMINISTERED TO SUBJECTS WITH SEASONAL ALLERGIC RHINITIS DURING THE MOUNTAIN CEADAR POLLEN SEASON

PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, COMPARIATIVE TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF XX 300MG PO BID FOR 7 DYAS VS XX 500MG PO BID FOR 7 DYAS IN THE TREATMENT OF UNCOMPLICATED SKIN & SKIN STRUCTURE INFECTIONS

A RANDOMIZED, 24-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARRALLEL-GROUP STUDY TO EVALUATE EFFICACY, SAFETY AND TOLERABILITY OF XX (15MG BID) IN PATIENTS WITH CHRONIC PULOMANRY DISEASE (COPD)

A RANDOMIZED, DOUBLE BLIND, POLACEBO-CONTROLLED, TRIAL TO INVESTIGATE VIRAL SHEDDING IN HEALTHY CHILDREN (6 TO 18 MONTHS OF AGE) VACCINATED WITH TWO DOSES OF LIQUID FROMULATION OF XX VIRUS VACCINE, TRIVALENT, TYES A&B, LIVE COLD ADAPTED XX

A MULTI-CENTER, STRATIFIED, RANDOMIZED, DB, PARALLEL-GROUP, STEP-UP COMPARISON OF THE LEVEL OF ASTHMA CONTROL ACHIEVED WITH XX COBINATION XX DRY POWDER INHALER COMPARED WITH XX (ACCUHALER) ALONE IN ADULTS

A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, NON-INFERIORITY STUDY ASSESSING THE EFFECTS OF XX METERED DOSE INHALER 50 UG/DAY AND 200 UG/DAY (EX-VALVE) ADMINISTERED ONCE DAILY ON GROWTH IN CHILDREN WITH MILD PERSISTENT ASTHMA

A PHASE III, DB, DD, PARALLEL-GROUP, MULTI-CENTER, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF XX 400 UG/DAY, 800 UG/DAY (XX & XX 880 UG/DAY ADMINISTERED TWICE DAILY FOR 12 WEEKS IN THE TREATMENT OF SEVERE PERSISTENT ASTHMA IN CHILDREN

A PHASE IIA, COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF XX 100MG, 200MG, 400MG AND XX 500MG IN SUBJECTS WITH AECB

A PHASE III DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP, MULTICENTER, PLACEBO CONTROLLED, EFFICACY AND SAFETY STUDY OF XX 400 UG/DAY, AND XX 880 UG/DAY ADMINISTERED BID FOR 12 WEEKS IN THE TREATMENT OF SEVERE PERSISTANT ASTHMA IN ADOLESCENTS AND ADULTS

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, ONE YEAR, LONG TERM SAFETY STUDY OF XX OR XX METERED DOSE INHALER ADMINISTERED BID FOR THE TREATMENT OF SEVERE PERSISITENT ASTHMA IN ADOLESCENTS AND ADULTS

A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, NON-INFERIORITY STUDY ASSESSING THE EFFECTS OF XX DOSE INHALER 50 UG/DDAY AND 200 UG/DAY (EX-VALVE) ADMINISTERD ONCE DAILY ON GROWTH IN CHILDREN WITH MILD PERSISTENT ASTHMA

A STRATIFITED RANDOMIZED, DB, PLACEBO CONTROLLED, PARALLED-GROUP, 12-WK TRIAL EVALUATING THE SAFET5Y AND EFFICACY OF THE XX 100/50 ONCE DAILY VS XX 100MG ONE DAILY AND PLACEBO IN SYMPTOMATIC PEDIATRIC PATIENTS (4-11) WITH ASTHMA

THE SAFETY AND EFFICACY OF XX VS XX. A ONE-YEAR, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, ACTIVE COMPARATOR STUDY

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF INHALED XX 10MG ADMINISTERED ONCE A DAY FOR 28 DAYS IN THE PREVENTION OF SYMPTOMATIC INFUENZA A & B VIRAL INFECTIONS IN COMMUNITY ACQUIRED PNEUMONIA

12 WEEKS TREATMENT WITH 250M UG XX VS. PLACEBO IN PATIENTS WITH ASTHMA

A PHASE II, DB, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, EFFICACY, SAFETY AQND DOSE RESPONSE STUDY OF XX 50, 100, & 200 UG/DAY ADMINISTERED ONCE DAILY FOR 12 WEEKS IN THE TREATMENT OF CHILDREN WITH PERSISTENT ASTHMA

A 12 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER STUDY OF THE EFFECTS OF 3 DIFFERENT DOSES OF ENTERIC COATED XX ON LEVELS OF C-REACTIVE PROTEIN IN WOMEN WHO INITIATE HORMONE REPLACEMENT THERAPY

THE EVALUATION OF XX ADMINISTERED IN SUBJECST WITH SAR DURING THE MOUNTIAN CEDAR POLLEN SEASON

THE EFFECACY AND SAFETY OF 5 DAYS ORAL XX (XX 800MG ONCE DAILY) VS. 10 DAYS ORAL XX (500 MG BID) IN THE TREATMENT OF ACUTE EXACERTATION OF CHRONIC BRONCHITIS (AECB)

A MULTICETNER, RANDOMIZED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE LONG TERM OF XX 50/500 UG BD, XX 50 UG BD AND XX 500 UG BD, ALL DELIVERED VIA XX INHALER, ON THE SURIVAL OF SUBJECTS WITH CHRONIC PULONARY DISEASE (COPD) OVER 3 YEARS OF TREATMENT

A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF XX 500MG SUPPRESSIVE THERAPY IN THE REDUCTION OF ANXIETY ASSOCIATED GENITAL HERPES

A PHASE III EVALUATOR BLIND, RANDOMIZED, PARALLEL GROUP STUDY TO DETERMINE THE EFFECTS OF THE XX PATCH, XX 2MG, ON THE HEALING OF RECURRENT MINOR APHTHOUS ULCERS AS COMPARED WITH XX PATCHES OR NO TREATMENT

A RANDOMIZED, THRID PARTY BLIND, MULTICENTER TRIAL COMPARING THE EFFICACY AND SAFETY OF XX FOR 3 WEEKS VS. XX FOR 6 WEEKS VS. X FOR 6 WEEKS GIVEN DAILY TO PEDIATRIC PATIENT WITH TINEA CAPITIS

AN OPEN LABEL, MULTICENTER, TRIAL OF XX FOR 6 WEEKS GIVEN ONCE DAILY TO PEDIATRIC PATIENTS WITH TINEA CAPITIS

A PHASE 2 COMPARATIVE STUDY OF THE SAFETY AND EFFICACY OF THREE ORAL DOSES OF XX FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS

A 6 WEEK, RANDOMIZED, OPEN LABEL, COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF XX AND XX IN THE TREATMENT OF HYPERCHOLESTEROLEMIA IN SOUTH ASIAN SUBJECTS

A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY AND EFFICACY OF XX IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS

A PILOT STUDY TO INVESTIGATE THE EFFECTS OF XX ON EPISODES OF ACUTE SINUSITIS WHEN ADMINISTERED AT THE “FIRST SIGN” OF SINUS SYMPTOMS

A RANDOMIZED, DOUBLE BLIND, PARALLEl GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF XX 10MG DAILY VS. PLACEBO IN SUBJECTS WHO HAVE USED XX TO TREAT THEIR ALLERGIC RHINITIS SYMPTO

SIGNATURE:_____ **DATE:**_____